- Global Pharma News & Resources

Opsens to Host Investor Webinar on Thursday, October 4 to Provide Update on Recent Developments

Opsens to Host Investor Webinar on Thursday, October 4 to Provide Update on Recent Developments

Canada NewsWire

QUEBEC CITY, Oct. 3, 2018

QUEBEC CITY, Oct. 3, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) will host an investor webinar and live Q&A session on

Thursday, October 4, 2018, at 4.05 p.m. EST.

The webinar will feature a presentation by Louis Laflamme, President and CEO of Opsens, who will discuss Opsens' high-performance proven technology, its market opportunity, its competitive advantages in interventional cardiology, more specifically in Fractional Flow Reserve (FFR), and other key developments.

To view the webinar, please visit

About Opsens Inc. ( or

Opsens focuses mainly on the measure of FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a 2nd-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 40,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.



Editor Details

Last Updated: 03-Oct-2018